BPC 157: The peptide with big claims and scant evidence STAT The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification BPC 157 Peptide Therapy Medical Spa in St. Joseph, MI The Aesthetics Lounge and Spa Peptide Therapy in Boise Specialized Treatment for First Responders Blueline Wellness BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn